NASDAQ:OPGN OpGen (OPGN) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free OPGN Stock Alerts $0.47 -0.02 (-4.08%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.5050-Day Range$0.40▼$0.7852-Week Range$0.17▼$3.84Volume332,181 shsAverage Volume1.33 million shsMarket Capitalization$5.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OpGen alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About OpGen Stock (NASDAQ:OPGN)OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Read More OPGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPGN Stock News HeadlinesMay 1, 2024 | americanbankingnews.comOpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.comApril 30, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesMay 3, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. April 29, 2024 | globenewswire.comOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 27, 2024 | investing.comOpGen CEO David Lazar buys additional shares worth $150kApril 26, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 23, 2024 | globenewswire.comOpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 22, 2024 | finance.yahoo.comOpGen, Inc. (OPGN)May 3, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. March 28, 2024 | msn.comShares Rip In Reaction To Activist Investor Becoming CEOMarch 27, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.08%March 26, 2024 | markets.businessinsider.comDow Gains 100 Points; McCormick Posts Upbeat ResultsMarch 26, 2024 | markets.businessinsider.comNasdaq Gains Over 50 Points; US Durable Goods Orders Rise In FebruaryMarch 26, 2024 | msn.comCrude Oil Moves Lower; TD SYNNEX Earnings Top EstimatesMarch 26, 2024 | msn.comWhy Is Penny Stock OpGen Trading Higher On Tuesday?March 26, 2024 | marketwatch.comOpGen Investor David Lazar Is Named CEOMarch 25, 2024 | globenewswire.comOpGen Announces Acquisition of Preferred Stock by David LazarMarch 20, 2024 | money.usnews.comOpgen IncFebruary 9, 2024 | msn.comOpGen Inc Reports Unregistered Equity Sales UpdateFebruary 9, 2024 | msn.comOpGen Inc. Extends Warrant Exercise Deadline to 2024December 17, 2023 | morningstar.comOpGen Inc OPGNDecember 13, 2023 | bizjournals.comRockville biotech OpGen fights to retain Nasdaq listing as business teetersNovember 15, 2023 | bizjournals.comRockville biotech OpGen shrinks headcount, scales down U.S. operationsNovember 15, 2023 | finanznachrichten.deOpGen, Inc.: OpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 14, 2023 | markets.businessinsider.comOpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 12, 2023 | seekingalpha.comOpGen surges after announcing private placementOctober 12, 2023 | finance.yahoo.comOpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross ProceedsSee More Headlines Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today5/03/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:OPGN CUSIPN/A CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,280,000.00 Net Margins-852.18% Pretax Margin-852.18% Return on Equity-316.30% Return on Assets-89.52% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.18 Sales & Book Value Annual Sales$2.61 million Price / Sales2.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.18Miscellaneous Outstanding Shares12,620,000Free Float12,457,000Market Cap$5.93 million OptionableNot Optionable Beta-0.56 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Oliver Schacht Ph.D. (Age 53)CEO, President & Director Comp: $408kMr. Albert Weber (Age 61)CFO & Corporate Secretary Comp: $317.5kMr. Johannes Bacher (Age 55)Chief Operating Officer Comp: $300kMr. Vadim Sapiro (Age 53)Chief Information Officer Comp: $300kKey CompetitorsAclarionNASDAQ:ACONBioNexus Gene LabNASDAQ:BGLCCentogeneNASDAQ:CNTGPsychemedicsNASDAQ:PMDPalisade BioNASDAQ:PALIView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 331,890 shares on 5/2/2024Ownership: 2.630%View All Institutional Transactions OPGN Stock Analysis - Frequently Asked Questions Should I buy or sell OpGen stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares. View OPGN analyst ratings or view top-rated stocks. How have OPGN shares performed in 2024? OpGen's stock was trading at $0.42 at the beginning of the year. Since then, OPGN shares have increased by 11.9% and is now trading at $0.47. View the best growth stocks for 2024 here. Are investors shorting OpGen? OpGen saw a drop in short interest in April. As of April 15th, there was short interest totaling 164,100 shares, a drop of 92.6% from the March 31st total of 2,230,000 shares. Based on an average trading volume of 1,650,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.4% of the shares of the company are short sold. View OpGen's Short Interest. When is OpGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OPGN earnings forecast. How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) released its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to analysts' expectations of $0.90 million. OpGen had a negative trailing twelve-month return on equity of 316.30% and a negative net margin of 852.18%. During the same period in the previous year, the business earned ($2.60) earnings per share. When did OpGen's stock split? OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did OpGen IPO? OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager. Who are OpGen's major shareholders? OpGen's stock is owned by many different retail and institutional investors. Top institutional investors include Chase Investment Counsel Corp (2.63%). Insiders that own company stock include Johannes Bacher and Oliver Schacht. View institutional ownership trends. How do I buy shares of OpGen? Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPGN) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
